Targeting the CCL5–CCR5 axis protects against chemoresistant mesothelioma development through macrophage reprogramming
Cancer Letters · 2026-11 · 218950
DOI: 10.1016/j.canlet.2026.218950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-11. Verfasst von Laura Gerardelli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Tumor and Developmental Biology, GIGA Institute, University of Liège, Liège, Belgium. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Fund for Scientific Research, Fondation contre le Cancer, University of Liège.
Abstract (Originalsprache)
Treatment resistance in pleural mesothelioma (PM) is a clinical challenge. Cisplatin-based chemotherapy remains a cornerstone of treatment, but responses are transient as resistant tumor cells drive disease progression. The contribution of the tumor immune microenvironment to chemoresistance is poorly understood so far. Using cisplatin-resistant murine (AB12, PM27) and human (MSTO-211H) PM models combined with transcriptomics, immune profiling and functional assays, we identify a key role for the CCL5-CCR5 axis in shaping an immunosuppressive niche that supports tumor progression. Resistant cells upregulate and secrete high levels of CCL5, leading to enhanced tumor growth in vivo. Immune profiling of tumor microenvironment reveals a marked recruitment of CCR5+ macrophages displaying an immunosuppressive phenotype characterized by reduced inflammatory activity. Mechanistically, tumor-derived CCL5 promotes macrophage recruitment and polarization toward a pro-tumoral state through CCR5 signaling. Disruption of this axis, either by pharmacological inhibition of CCR5 using maraviroc or by genetic silencing of CCL5, reduces macrophage infiltration and significantly impairs tumor progression. These findings reveal microenvironment-driven mechanism of chemoresistance in PM and identify the CCL5-CCR5 axis as a key vulnerability. Targeting this pathway may therefore represent a promising therapeutic strategy to limit the progression of cisplatin-resistant mesothelioma by disrupting the tumor-supportive immune microenvironment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Tumor and Developmental Biology, GIGA Institute, University of Liège, Liège, Belgium.
- Faculty of Veterinary Medicine, University of Liège, Liège, Belgium; Laboratory of Immunophysiology, GIGA Institute, University of Liège, Liège, Belgium.
- Metastasis Research Laboratory, GIGA Institute, University of Liège, Liège, Belgium.
- Faculty of Veterinary Medicine, University of Liège, Liège, Belgium; Laboratory of Immunophysiology, GIGA Institute, University of Liège, Liège, Belgium; Walloon Excellence in Life Sciences and Biotechnology (WELBIO) De…
- Laboratory of Tumor and Developmental Biology, GIGA Institute, University of Liège, Liège, Belgium; Department of Respiratory diseases, CHU Liege and University of Liège, Liège, Belgium. Electronic address: Didier.Catal…
Förderung
- Fund for Scientific Research
- Fondation contre le Cancer
- University of Liège
- Léon Fredericq Foundation
Zitieren
APA
Gerardelli, L., Havrics, E., Demanche, A., La Rocca, R., Lebrun, M., Bottero, B., Bosmans, M., Bellefroid, M., Perin, F., Morbidelli, M., Peiffer, R., Crake, R., Marichal, T., Nokin, M. J., & Cataldo, D. (2026). Targeting the CCL5–CCR5 axis protects against chemoresistant mesothelioma development through macrophage reprogramming. Cancer Letters, 218950. https://doi.org/10.1016/j.canlet.2026.218950
Vancouver
Gerardelli L, Havrics E, Demanche A, La Rocca R, Lebrun M, Bottero B, et al. Targeting the CCL5–CCR5 axis protects against chemoresistant mesothelioma development through macrophage reprogramming. Cancer Letters. 2026:218950. doi:10.1016/j.canlet.2026.218950
BibTeX
@article{Gerardelli2026,
author = {Gerardelli, Laura and Havrics, Eszter and Demanche, Alicia and La Rocca, Raphaël and Lebrun, Maxime and Bottero, Benedetta and Bosmans, Maëlle and Bellefroid, Marine and Perin, Fabienne and Morbidelli, Marco and Peiffer, Raphaël and Crake, Rebekah and Marichal, Thomas and Nokin, Marie-Julie and Cataldo, Didier},
title = {Targeting the CCL5–CCR5 axis protects against chemoresistant mesothelioma development through macrophage reprogramming},
journal = {Cancer Letters},
year = {2026},
pages = {218950},
doi = {10.1016/j.canlet.2026.218950}
}
EUVIMED